Novel Approaches in the Treatment of Depression: A free educational program exclusively for patients, families, and friends
The Massachusetts General Hospital Department of Psychiatry invites you to attend the June symposium Novel Approaches in the Treatment of Depression.
The program will cover topics related to depression that are of importance to those seeking or currently receiving psychiatric treatment for themselves or loved ones.
Participants will learn about a variety of treatment approaches, including neuropsychiatric therapies (also known as “somatic” therapies), with a focus on the recently FDA-approved Transcranial Magenetic Stimulation (TMS) therapy, as well as other experimental brain stimulation therapies. The course will also cover novel and creative antidepressant combination strategies, many of which are not yet formally tested scientifically but have proven effective in the clinical setting when sanctioned treatments and combination therapies have not worked. The placebo effect will be explored, how it impacts treatment response in clinical practice, and how it may limit clinical research on antidepressants. The course will also address the question of why most available antidepressants have proven of limited benefit, and explore new paradigms for developing faster and more effective antidepressants, based on biological targeting strategies. In addition to medication-based and somatic treatments, participants will also learn how Acceptance and Commitment Therapy (ACT) has advanced the management of depression and of psychiatric illness in general.
The symposium will also include presentations by members of a patient and family panel who will give a first-hand account of their journey through the recovery process and engage in a dialogue with participants, followed by a 15 minute question and answer session. We are grateful to these individuals for sharing their stories publicly and contributing their time to help others deal with the issues of depression.
We hope this program helps you and your family in the journey toward wellness.
About the Massachusetts General Hospital Department of Psychiatry
The Department of Psychiatry was established in 1934. In the course of seven decades, its scientists and clinicians have made significant contributions to the understanding and treatment of mental health disorders. Today, the department includes more than 600 affiliated psychiatrists and psychologists and has the largest clinical research program in the hospital, which includes research in neuroscience, genetics, and the assessment of new and established treatments for mental health disorders.
Clinical Trials Network & Institute (CTNI) is part of the Massachusetts General Hospital Department of Psychiatry. Through this program, sponsors collaborate with researchers who are recognized as world leaders in many areas of psychiatric research, including anxiety, depression, bipolar disorder, women’s mental health, schizophrenia, geriatrics, Alzheimer’s disease, phamacogenetics, neuroimaging, and pediatric psychopharmacology. CTNI has extensive experience over the past 25 years in industry-sponsored multi-center clinical trials. By exploring the brain science, genetics, and neurobiology of psychiatric disorders, the MGH CTNI has been instrumental in the development of novel treatments and surrogate markers of illness and therapeutic response.
The Depression Clinical and Research Program (DCRP) ) is one of the leading centers for the study of unipolar depression worldwide. In addition to carrying out significant research activities, the DCRP is involved in delivering the highest quality clinical care through the Outpatient Psychiatry Division at MGH. The clinicians of the DCRP are known for providing comprehensive consultations and treatment to patients with depression and for employing sophisticated, state of the art pharmacotherapy strategies.
The MGH Psychiatry Academy (MGH-PA) was launched in 2005 to bring high quality continuing medical education to psychiatrists, primary care doctors, psychologists, social workers, and other health professionals around the world through live programming and the Internet. Since 2008 the MGH-PA has had more than 35,000 healthcare providers participate in live symposia and on-line activities. In 2010, the MGH-PA assumed responsibility for patient education programs that were formerly provided by the Mood and Anxiety Disorders Institute (MADI) Resource Center. The MGH-PA is now providing education for individuals, families, non-professional caregivers, and the community about mental health, translating the latest research advances into practical information to help people work with their doctors toward the most accurate diagnosis and the best possible treatment results.